Top Globe News – Lifestyle

Author: AgomAb Therapeutics N.V.

Agomab to Participate in Upcoming Conferences

May 14, 2026
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

April 29, 2026
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

March 26, 2026